Enhertu (fam-trastuzumab deruxtecan-nxki) received FDA regular approval for adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within 6 months of completing therapy.
Scientific advances have produced therapies that allow some people with metastatic breast cancer to live longer and better. We want that progress to continue, and we will continue to fight for the right research necessary to achieve it.
